DE2500110C2 - - Google Patents
Info
- Publication number
- DE2500110C2 DE2500110C2 DE2500110A DE2500110A DE2500110C2 DE 2500110 C2 DE2500110 C2 DE 2500110C2 DE 2500110 A DE2500110 A DE 2500110A DE 2500110 A DE2500110 A DE 2500110A DE 2500110 C2 DE2500110 C2 DE 2500110C2
- Authority
- DE
- Germany
- Prior art keywords
- phenylpropylamine
- methyl
- dimethyl
- ether
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 16
- 150000001412 amines Chemical class 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- -1 3-chloro-1- (substituted-phenoxy) propylbenzene Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 46
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 239000000460 chlorine Substances 0.000 description 16
- 230000002631 hypothermal effect Effects 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 229940076279 serotonin Drugs 0.000 description 12
- 239000000935 antidepressant agent Substances 0.000 description 11
- 229940005513 antidepressants Drugs 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 10
- 229960004046 apomorphine Drugs 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 9
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 9
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 9
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 9
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 9
- 229960003147 reserpine Drugs 0.000 description 9
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 9
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 229960003914 desipramine Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- ITJNARMNRKSWTA-UHFFFAOYSA-N nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 description 6
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 5
- 230000008485 antagonism Effects 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000155 melt Substances 0.000 description 5
- 229960002748 norepinephrine Drugs 0.000 description 5
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000012259 ether extract Substances 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- LCEURBZEQJZUPV-UHFFFAOYSA-N hydron;3-(2-methoxyphenoxy)-n-methyl-3-phenylpropan-1-amine;chloride Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC LCEURBZEQJZUPV-UHFFFAOYSA-N 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000004089 psychotropic agent Substances 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- SDWVTCNYPZSVQY-UHFFFAOYSA-N (1-bromo-3-chloropropyl)benzene Chemical compound ClCCC(Br)C1=CC=CC=C1 SDWVTCNYPZSVQY-UHFFFAOYSA-N 0.000 description 3
- VELGOYBSKBKQFF-UHFFFAOYSA-N 3-(dimethylamino)-1-phenylpropan-1-ol Chemical compound CN(C)CCC(O)C1=CC=CC=C1 VELGOYBSKBKQFF-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229960000836 amitriptyline Drugs 0.000 description 3
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 125000002147 dimethylamino group Chemical class [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 150000002367 halogens Chemical group 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- QUFZVVNFYXEIAK-UHFFFAOYSA-N n,n-dimethyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCN(C)C)OC1=CC=C(C(F)(F)F)C=C1 QUFZVVNFYXEIAK-UHFFFAOYSA-N 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000013275 serotonin uptake Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- MAZJWUVQYXBVCU-UHFFFAOYSA-N 1-(3-chloro-1-phenylpropoxy)-2-methoxybenzene Chemical compound COC1=CC=CC=C1OC(CCCl)C1=CC=CC=C1 MAZJWUVQYXBVCU-UHFFFAOYSA-N 0.000 description 2
- XXLWNLKEOWWHDC-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-methylpropan-2-amine Chemical compound CNC(C)CC1=CC=C(Cl)C=C1 XXLWNLKEOWWHDC-UHFFFAOYSA-N 0.000 description 2
- JSZBBIFZABKVLG-UHFFFAOYSA-N 3-(2-methoxyphenoxy)-n-methyl-3-phenylpropan-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC JSZBBIFZABKVLG-UHFFFAOYSA-N 0.000 description 2
- QMNXJNURJISYMS-UHFFFAOYSA-N 3-(dimethylamino)-1-phenylpropan-1-one Chemical compound CN(C)CCC(=O)C1=CC=CC=C1 QMNXJNURJISYMS-UHFFFAOYSA-N 0.000 description 2
- XCDGTYXHQMKRBJ-UHFFFAOYSA-N 3-[(2-methoxyphenyl)methoxy]-n,n-dimethyl-3-phenylpropan-1-amine Chemical compound COC1=CC=CC=C1COC(CCN(C)C)C1=CC=CC=C1 XCDGTYXHQMKRBJ-UHFFFAOYSA-N 0.000 description 2
- KJBOLGFVUPJVKR-UHFFFAOYSA-N 3-chloro-n,n-dimethyl-3-phenylpropan-1-amine;hydrochloride Chemical compound Cl.CN(C)CCC(Cl)C1=CC=CC=C1 KJBOLGFVUPJVKR-UHFFFAOYSA-N 0.000 description 2
- XZBXAYCCBFTQHH-UHFFFAOYSA-N 3-chloropropylbenzene Chemical compound ClCCCC1=CC=CC=C1 XZBXAYCCBFTQHH-UHFFFAOYSA-N 0.000 description 2
- LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 241000272201 Columbiformes Species 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 239000003420 antiserotonin agent Substances 0.000 description 2
- 239000003637 basic solution Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229960001867 guaiacol Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- CKOSCBUBUNGPOY-UHFFFAOYSA-N n-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 CKOSCBUBUNGPOY-UHFFFAOYSA-N 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- WWPITPSIWMXDPE-UHFFFAOYSA-N para-chloroamphetamine Chemical compound CC(N)CC1=CC=C(Cl)C=C1 WWPITPSIWMXDPE-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- JQWYTSHFVIDUHA-UHFFFAOYSA-M sodium;2-hydroxy-3-methoxybenzoate Chemical compound [Na+].COC1=CC=CC(C([O-])=O)=C1O JQWYTSHFVIDUHA-UHFFFAOYSA-M 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- KSYQJOYVRKIAMP-BTJKTKAUSA-N (Z)-but-2-enedioic acid 3-(4-fluorophenoxy)-N-methyl-3-phenylpropan-1-amine Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=CC=1C(CCNC)OC1=CC=C(F)C=C1 KSYQJOYVRKIAMP-BTJKTKAUSA-N 0.000 description 1
- VEASJAWDVOWYTN-BTJKTKAUSA-N (Z)-but-2-enedioic acid 3-(4-methoxyphenoxy)-N-methyl-3-phenylpropan-1-amine Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=CC=1C(CCNC)OC1=CC=C(OC)C=C1 VEASJAWDVOWYTN-BTJKTKAUSA-N 0.000 description 1
- PIDUGQOHPNWZSF-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-(2-chlorophenoxy)-n,n-dimethyl-3-phenylpropan-1-amine Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=CC=1C(CCN(C)C)OC1=CC=CC=C1Cl PIDUGQOHPNWZSF-BTJKTKAUSA-N 0.000 description 1
- NFRXMCMXFSQRPQ-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-(2-methoxyphenoxy)-n,n-dimethyl-3-phenylpropan-1-amine Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC=CC=C1OC(CCN(C)C)C1=CC=CC=C1 NFRXMCMXFSQRPQ-BTJKTKAUSA-N 0.000 description 1
- AGDPIQBPRFRIEF-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-(4-fluorophenoxy)-n,n-dimethyl-3-phenylpropan-1-amine Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=CC=1C(CCN(C)C)OC1=CC=C(F)C=C1 AGDPIQBPRFRIEF-BTJKTKAUSA-N 0.000 description 1
- ZTEPGFPSUIUPDX-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-(4-methoxyphenoxy)-n,n-dimethyl-3-phenylpropan-1-amine Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1OC(CCN(C)C)C1=CC=CC=C1 ZTEPGFPSUIUPDX-BTJKTKAUSA-N 0.000 description 1
- VHLIZJXLAPNSPQ-UHFFFAOYSA-N 1-(2-methoxyphenoxy)-n-methylpropan-1-amine Chemical compound CCC(NC)OC1=CC=CC=C1OC VHLIZJXLAPNSPQ-UHFFFAOYSA-N 0.000 description 1
- MKZHJJQCUIZEDE-UHFFFAOYSA-N 1-[(2-hydroxy-3-naphthalen-1-yloxypropyl)-propan-2-ylamino]-3-naphthalen-1-yloxypropan-2-ol Chemical compound C1=CC=C2C(OCC(O)CN(CC(O)COC=3C4=CC=CC=C4C=CC=3)C(C)C)=CC=CC2=C1 MKZHJJQCUIZEDE-UHFFFAOYSA-N 0.000 description 1
- YZZWXSKVXAETIR-UHFFFAOYSA-N 1-[(3-chloro-1-phenylpropoxy)methyl]-2-methoxybenzene Chemical compound COC1=CC=CC=C1COC(CCCl)C1=CC=CC=C1 YZZWXSKVXAETIR-UHFFFAOYSA-N 0.000 description 1
- JSUAJTLKVREZHV-UHFFFAOYSA-N 1-[4-(1-pyrrolidinyl)but-2-ynyl]pyrrolidine Chemical compound C1CCCN1CC#CCN1CCCC1 JSUAJTLKVREZHV-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- OMNGOGILVBLKAS-UHFFFAOYSA-N 2-methoxyphenol Chemical compound COC1=CC=CC=C1O.COC1=CC=CC=C1O OMNGOGILVBLKAS-UHFFFAOYSA-N 0.000 description 1
- GRNCTJVYPJXPAY-UHFFFAOYSA-N 2-methoxyphenol;sodium Chemical compound [Na].COC1=CC=CC=C1O GRNCTJVYPJXPAY-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- UGYLBIAQUSWTRS-UHFFFAOYSA-N 2-phenoxy-2-phenylethanamine Chemical group C=1C=CC=CC=1C(CN)OC1=CC=CC=C1 UGYLBIAQUSWTRS-UHFFFAOYSA-N 0.000 description 1
- HQGKFUOTGWAAFP-UHFFFAOYSA-N 3-(2,4-difluorophenoxy)-n,n-dimethyl-3-phenylpropan-1-amine;2,4-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O.C=1C=CC=CC=1C(CCN(C)C)OC1=CC=C(F)C=C1F HQGKFUOTGWAAFP-UHFFFAOYSA-N 0.000 description 1
- IUYJQDJVTNCATL-UHFFFAOYSA-N 3-(2-bromophenoxy)-n,n-dimethyl-3-phenylpropan-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=CC=CC=1C(CCN(C)C)OC1=CC=CC=C1Br IUYJQDJVTNCATL-UHFFFAOYSA-N 0.000 description 1
- VCVDBSBGDYATJL-UHFFFAOYSA-N 3-(2-ethoxyphenoxy)-n,n-dimethyl-3-phenylpropan-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.CCOC1=CC=CC=C1OC(CCN(C)C)C1=CC=CC=C1 VCVDBSBGDYATJL-UHFFFAOYSA-N 0.000 description 1
- NOOFDMAHZDCRBT-UHFFFAOYSA-N 3-(2-fluorophenoxy)-N-methyl-3-phenylpropan-1-amine oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1F NOOFDMAHZDCRBT-UHFFFAOYSA-N 0.000 description 1
- KCNDHVXTLLIHHC-UHFFFAOYSA-N 3-(2-fluorophenoxy)-n,n-dimethyl-3-phenylpropan-1-amine;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CCN(C)C)OC1=CC=CC=C1F KCNDHVXTLLIHHC-UHFFFAOYSA-N 0.000 description 1
- YMASWMGBWHSISX-UHFFFAOYSA-N 3-(2-methoxyphenoxy)-3-phenylpropan-1-amine Chemical compound COC1=CC=CC=C1OC(CCN)C1=CC=CC=C1 YMASWMGBWHSISX-UHFFFAOYSA-N 0.000 description 1
- GAPORDRWLPABHD-UHFFFAOYSA-N 3-(3,4-dimethoxyphenoxy)-n,n-dimethyl-3-phenylpropan-1-amine;4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1.C1=C(OC)C(OC)=CC=C1OC(CCN(C)C)C1=CC=CC=C1 GAPORDRWLPABHD-UHFFFAOYSA-N 0.000 description 1
- YUSSKJQUXVWCFH-UHFFFAOYSA-N 3-(3-chlorophenoxy)-N-methyl-3-phenylpropan-1-amine oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=CC=CC=1C(CCNC)OC1=CC=CC(Cl)=C1 YUSSKJQUXVWCFH-UHFFFAOYSA-N 0.000 description 1
- QMLOPUISAXPWPX-UHFFFAOYSA-N 3-(3-chlorophenoxy)-n,n-dimethyl-3-phenylpropan-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=CC=CC=1C(CCN(C)C)OC1=CC=CC(Cl)=C1 QMLOPUISAXPWPX-UHFFFAOYSA-N 0.000 description 1
- LUDILMKBJZIMJP-UHFFFAOYSA-N 3-(3-fluorophenoxy)-N-methyl-3-phenylpropan-1-amine oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=CC=CC=1C(CCNC)OC1=CC=CC(F)=C1 LUDILMKBJZIMJP-UHFFFAOYSA-N 0.000 description 1
- KYVSJUCXUDDEJJ-UHFFFAOYSA-N 3-(3-methoxyphenoxy)-N-methyl-3-phenylpropan-1-amine oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=CC=CC=1C(CCNC)OC1=CC=CC(OC)=C1 KYVSJUCXUDDEJJ-UHFFFAOYSA-N 0.000 description 1
- ZWGXKQCXHURVCH-UHFFFAOYSA-N 3-(3-methoxyphenoxy)-n,n-dimethyl-3-phenylpropan-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.COC1=CC=CC(OC(CCN(C)C)C=2C=CC=CC=2)=C1 ZWGXKQCXHURVCH-UHFFFAOYSA-N 0.000 description 1
- DHCOUFLPQVSDFW-UHFFFAOYSA-N 3-(4-fluorophenoxy)-N-methyl-3-phenylpropan-1-amine oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=CC=CC=1C(CCNC)OC1=CC=C(F)C=C1 DHCOUFLPQVSDFW-UHFFFAOYSA-N 0.000 description 1
- OZBPQORRHCXDPN-UHFFFAOYSA-N 3-(4-iodophenoxy)-n-methyl-3-phenylpropan-1-amine;prop-2-ynoic acid Chemical compound OC(=O)C#C.C=1C=CC=CC=1C(CCNC)OC1=CC=C(I)C=C1 OZBPQORRHCXDPN-UHFFFAOYSA-N 0.000 description 1
- DKNDBIIKSJWQFL-UHFFFAOYSA-N 3-(dimethylamino)-1-phenylpropan-1-one;hydron;chloride Chemical compound Cl.CN(C)CCC(=O)C1=CC=CC=C1 DKNDBIIKSJWQFL-UHFFFAOYSA-N 0.000 description 1
- KRZRJWMDGIMGJZ-UHFFFAOYSA-N 3-[(2-methoxyphenyl)methoxy]-n-methyl-3-phenylpropan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OCC1=CC=CC=C1OC KRZRJWMDGIMGJZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- YJWZCUHMWDKUES-UHFFFAOYSA-N 3-chloro-n,n-dimethyl-3-phenylpropan-1-amine Chemical compound CN(C)CCC(Cl)C1=CC=CC=C1 YJWZCUHMWDKUES-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- XYWLZHPZECQHMB-UHFFFAOYSA-N 3-phenoxy-3-phenylpropan-1-amine Chemical group C=1C=CC=CC=1C(CCN)OC1=CC=CC=C1 XYWLZHPZECQHMB-UHFFFAOYSA-N 0.000 description 1
- BAYGVMXZJBFEMB-UHFFFAOYSA-N 4-(trifluoromethyl)phenol Chemical compound OC1=CC=C(C(F)(F)F)C=C1 BAYGVMXZJBFEMB-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000027559 Appetite disease Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- DCYPAEGZLDIMCJ-UHFFFAOYSA-N C(C(=O)O)(=O)O.CN(CCCC1=CC=CC=C1)OC1=CC=C(C=C1)Cl Chemical compound C(C(=O)O)(=O)O.CN(CCCC1=CC=CC=C1)OC1=CC=C(C=C1)Cl DCYPAEGZLDIMCJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 238000006683 Mannich reaction Methods 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 1
- 208000014993 Pituitary disease Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- UUAOCVDBRMFQSB-UHFFFAOYSA-N [3-chloro-1-(1-methoxycyclohexa-2,4-dien-1-yl)oxypropyl]benzene Chemical compound C=1C=CC=CC=1C(CCCl)OC1(OC)CC=CC=C1 UUAOCVDBRMFQSB-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003555 analeptic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003326 anti-histaminergic effect Effects 0.000 description 1
- 230000001705 anti-serotonergic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- MSQDVGOEBXMPRF-UHFFFAOYSA-N cyclohexane;propan-2-one Chemical compound CC(C)=O.C1CCCCC1 MSQDVGOEBXMPRF-UHFFFAOYSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- ODLMAHJVESYWTB-UHFFFAOYSA-N ethylmethylbenzene Natural products CCCC1=CC=CC=C1 ODLMAHJVESYWTB-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- MOUHUYNXIVXFOJ-UHFFFAOYSA-N methyl-[1-[4-(trifluoromethyl)phenoxy]propyl]cyanamide Chemical compound N#CN(C)C(CC)OC1=CC=C(C(F)(F)F)C=C1 MOUHUYNXIVXFOJ-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- VGFCJPBWRLGKKE-UHFFFAOYSA-N n,n-dimethyl-3-phenyl-3-(2-propan-2-yloxyphenoxy)propan-1-amine;2-phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1.CC(C)OC1=CC=CC=C1OC(CCN(C)C)C1=CC=CC=C1 VGFCJPBWRLGKKE-UHFFFAOYSA-N 0.000 description 1
- CLTYMRLPENTEJA-UHFFFAOYSA-N n,n-dimethyl-3-phenyl-3-(2-propan-2-yloxyphenoxy)propan-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.CC(C)OC1=CC=CC=C1OC(CCN(C)C)C1=CC=CC=C1 CLTYMRLPENTEJA-UHFFFAOYSA-N 0.000 description 1
- ZGYRVDCGFXYGBN-UHFFFAOYSA-N n,n-dimethyl-3-phenyl-3-[3-(trifluoromethyl)phenoxy]propan-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=CC=CC=1C(CCN(C)C)OC1=CC=CC(C(F)(F)F)=C1 ZGYRVDCGFXYGBN-UHFFFAOYSA-N 0.000 description 1
- PITXIOMEECXWFR-UHFFFAOYSA-N n,n-dimethyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=CC=CC=1C(CCN(C)C)OC1=CC=C(C(F)(F)F)C=C1 PITXIOMEECXWFR-UHFFFAOYSA-N 0.000 description 1
- QYCDPUQGBCFZRJ-UHFFFAOYSA-N n-(2-methoxyphenoxy)-3-phenylpropan-1-amine Chemical compound COC1=CC=CC=C1ONCCCC1=CC=CC=C1 QYCDPUQGBCFZRJ-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000012154 norepinephrine uptake Effects 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- POVHYPPRXRSZCT-UHFFFAOYSA-N oxalic acid;3-phenylpropan-1-amine Chemical compound OC(=O)C(O)=O.NCCCC1=CC=CC=C1 POVHYPPRXRSZCT-UHFFFAOYSA-N 0.000 description 1
- QYWYGVROYHZRFV-UHFFFAOYSA-N oxalic acid;propan-1-amine Chemical compound CCCN.OC(=O)C(O)=O QYWYGVROYHZRFV-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 238000000718 qrs complex Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000012313 reversal agent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/432,379 US4314081A (en) | 1974-01-10 | 1974-01-10 | Arloxyphenylpropylamines |
| KR1019750000261A KR800001009B1 (ko) | 1975-01-09 | 1975-01-09 | 아릴옥시페닐프로필 아민류의 제조방법 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2500110A1 DE2500110A1 (de) | 1975-07-17 |
| DE2500110C2 true DE2500110C2 (OSRAM) | 1987-06-11 |
Family
ID=26625843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752500110 Granted DE2500110A1 (de) | 1974-01-10 | 1975-01-03 | 3-aryloxy-3-phenylpropylamine und verfahren zu ihrer herstellung |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4314081A (OSRAM) |
| JP (1) | JPS5939418B2 (OSRAM) |
| AR (3) | AR205633A1 (OSRAM) |
| AT (1) | AT336000B (OSRAM) |
| BE (1) | BE824255A (OSRAM) |
| BG (3) | BG26192A3 (OSRAM) |
| CA (1) | CA1051034A (OSRAM) |
| CH (1) | CH609675A5 (OSRAM) |
| CS (1) | CS189680B2 (OSRAM) |
| DD (1) | DD118613A5 (OSRAM) |
| DE (1) | DE2500110A1 (OSRAM) |
| DK (1) | DK140430B (OSRAM) |
| ES (1) | ES433720A1 (OSRAM) |
| FR (1) | FR2257288B1 (OSRAM) |
| GB (1) | GB1493961A (OSRAM) |
| IE (1) | IE40346B1 (OSRAM) |
| NL (2) | NL181654C (OSRAM) |
| PH (1) | PH11652A (OSRAM) |
| RO (2) | RO70660A (OSRAM) |
| SE (1) | SE412906B (OSRAM) |
| SU (1) | SU1005655A3 (OSRAM) |
| YU (3) | YU36915B (OSRAM) |
| ZA (1) | ZA7532B (OSRAM) |
Families Citing this family (201)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4626549A (en) * | 1974-01-10 | 1986-12-02 | Eli Lilly And Company | Treatment of obesity with aryloxyphenylpropylamines |
| US4584404A (en) * | 1974-01-10 | 1986-04-22 | Eli Lilly And Company | Substituted phenoxyphenylproply dimethylamines |
| JPS5283811A (en) * | 1976-01-01 | 1977-07-13 | Lilly Co Eli | Aryloxy phenyl propylamines and their salts |
| GB1570613A (en) * | 1976-10-27 | 1980-07-02 | Akzo Nv | Biologically active tricyclic compounds and pharmaceutical compositions containing same |
| IL56369A (en) * | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
| FR2432500A1 (fr) * | 1978-02-24 | 1980-02-29 | Roussel Uclaf | Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments |
| FR2455571A2 (fr) * | 1979-02-15 | 1980-11-28 | Roussel Uclaf | Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre medicaments |
| DE3017812A1 (de) * | 1980-05-09 | 1981-11-12 | Merck Patent Gmbh, 6100 Darmstadt | Cyclopropanderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung |
| US4430319A (en) | 1982-05-21 | 1984-02-07 | State University Of New York | Radioactive iodine labeled phenolic amines |
| US4824868A (en) * | 1982-09-07 | 1989-04-25 | Ciba-Geigy Corporation | Propylamine derivatives useful for the treatment of dementia |
| US4692469A (en) * | 1982-09-07 | 1987-09-08 | Ciba-Geigy Corporation | Propylamine derivatives |
| US4590213A (en) * | 1983-04-08 | 1986-05-20 | Eli Lilly And Company | Anti-anxiety method |
| HU207282B (en) * | 1984-05-31 | 1993-03-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them |
| US4594358A (en) * | 1985-02-25 | 1986-06-10 | Eli Lilly And Company | Analgesic method |
| US4683235A (en) * | 1985-02-25 | 1987-07-28 | Eli Lilly And Company | Analgesic method |
| US4777291A (en) * | 1985-02-27 | 1988-10-11 | Eli Lilly And Company | Racemization process |
| US4956388A (en) * | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| US5135947A (en) * | 1987-04-09 | 1992-08-04 | Eli Lilly And Company | 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors |
| US5149714A (en) * | 1987-08-14 | 1992-09-22 | Merrell Dow Pharmaceuticals Inc. | Antidepressants |
| CA1327795C (en) * | 1987-08-14 | 1994-03-15 | Jules Freedman | Antidepressants which are aryloxy inadanamines |
| US4971998A (en) * | 1987-10-22 | 1990-11-20 | Massachusetts Institute Of Technology | Methods for treating the premenstrual or late luteal phase syndrome |
| US5223540A (en) * | 1987-10-22 | 1993-06-29 | Massachusetts Institute Of Technology | Method for treating the premenstrual or late luteal phase syndrome |
| US4876282A (en) * | 1987-11-25 | 1989-10-24 | Eli Lilly And Company | 1-Phenylalkylamines as selective serotonin uptake inhibitors |
| US4996235A (en) * | 1987-11-25 | 1991-02-26 | Eli Lilly And Company | 3,4-diphenylbutanamines |
| US5238959A (en) * | 1988-04-08 | 1993-08-24 | Eli Lilly And Company | 3-phenyloxy-3-phenyl propanamines |
| IL89854A (en) * | 1988-04-08 | 1994-02-27 | Lilly Co Eli | Phenoxypropanamines, the process for their preparation and medicinal preparations containing them |
| US5250571A (en) * | 1988-11-14 | 1993-10-05 | Eli Lilly And Company | (S)-norfluoxetine in method of inhibiting serotonin uptake |
| US4902710A (en) * | 1988-12-14 | 1990-02-20 | Eli Lilly And Company | Serotonin and norepinephrine uptake inhibitors |
| US5114976A (en) * | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| IT1228209B (it) * | 1989-01-10 | 1991-06-05 | Grato Magnone | Procedimento per la preparazione di fluoxetina cloridrato. |
| FI81083C (fi) * | 1989-03-03 | 1990-09-10 | Orion Yhtymae Oy | Ett foerbaettrat foerfarande foer framstaellning av n-metyl-3-(p-trifluormetylfenoxi)-3-fenylpropylamin hydroklorid. |
| US5166437A (en) * | 1989-03-03 | 1992-11-24 | Orion-Yhtyma Oy | Process for the preparation of fluoxetine |
| DK258389D0 (da) * | 1989-05-26 | 1989-05-26 | Ferrosan As | Aryloxyphenylpropylaminer, deres fremstilling og anvendelse |
| JPH0375680U (OSRAM) * | 1989-11-21 | 1991-07-30 | ||
| US5021426A (en) * | 1990-02-26 | 1991-06-04 | Merck & Co., Inc. | Method of traeting malaria with cyproheptadine derivatives |
| US5250572A (en) * | 1990-03-29 | 1993-10-05 | Eli Lilly And Company | (R)-norfluoxetine in method for occupying serotonin IC receptors |
| US5356934A (en) * | 1990-03-29 | 1994-10-18 | Eli Lilly And Company | Selected serotonin subtype receptor agonist to treat sleep apnea |
| US5589511A (en) * | 1990-08-13 | 1996-12-31 | Sepracor Inc. | Method for treating migraine headaches using optically pure S(+) fluoxetine |
| US5708035A (en) * | 1991-02-04 | 1998-01-13 | Sepracor Inc. | Methods of use and compositions of R(-) fluoxetine |
| ZA921292B (en) * | 1991-02-25 | 1993-08-23 | Lilly Co Eli | Treatment of lower urinary tract disorders. |
| US5136078A (en) * | 1991-02-26 | 1992-08-04 | Eli Lilly And Company | Synthesis of b-cyanohydrins |
| US5136079A (en) * | 1991-02-26 | 1992-08-04 | Eli Lilly And Company | Regioselective synthesis |
| US5320825A (en) * | 1991-05-01 | 1994-06-14 | Trustees Of The University Of Pennsylvania | Serotonin reuptake inhibitors for S.P.E.C.T. imaging |
| WO1993000811A1 (en) * | 1991-07-01 | 1993-01-21 | The General Hospital Corporation | Invertebrate phenylethanolamine transporter and the use thereof |
| IL99316A (en) | 1991-08-27 | 1995-03-15 | Teva Pharma | Production of fluoxetine and new intermediates |
| US5202319A (en) * | 1991-09-23 | 1993-04-13 | Hoechst-Roussel Pharmaceuticals Inc. | Substituted 3-amino-2,3,4,5-tetrahydro-1-aryloxy-3-benzazepines |
| DK0537915T3 (da) * | 1991-09-27 | 1995-11-27 | Lilly Co Eli | N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin |
| US5281624A (en) * | 1991-09-27 | 1994-01-25 | Eli Lilly And Company | N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof |
| HU9202128D0 (en) * | 1992-06-26 | 1992-10-28 | Richter Gedeon Vegyeszet | Method for producing n-methyl-(3-phenyl-3-(4-[trifluoro-methyl])-phenooxi-)-amine |
| EP0576766A1 (en) * | 1992-06-29 | 1994-01-05 | Novo Nordisk A/S | Propanolamine derivatives, their preparation and use |
| US7087765B2 (en) * | 1995-06-07 | 2006-08-08 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| US6017965A (en) * | 1993-02-08 | 2000-01-25 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
| CA2134038C (en) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
| ES2082723B1 (es) * | 1994-07-20 | 1996-10-01 | Lilly Sa | Formulacion farmaceutica de fluoxetina en forma dispersable. |
| EP0714663A3 (en) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
| US5741789A (en) | 1995-01-17 | 1998-04-21 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| US5576321A (en) * | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| ES2101650B1 (es) * | 1995-06-29 | 1998-01-16 | Lilly Sa | Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfenoxi) propilamina. |
| US6548084B2 (en) * | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| ES2101654B1 (es) * | 1995-07-24 | 1998-01-16 | Lilly Sa | Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina. |
| ES2101655B1 (es) * | 1995-07-28 | 1998-01-16 | Lilly Sa | Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina. |
| ES2103680B1 (es) * | 1995-08-03 | 1998-04-01 | Lilly Sa | Procedimiento de preparacion de n-metil-3-fenil-3- (p-trifluorometilfenoxi)propilamina. |
| PT759299E (pt) * | 1995-08-16 | 2000-09-29 | Lilly Co Eli | Potenciacao da resposta de serotonina |
| ES2103681B1 (es) * | 1995-09-19 | 1998-04-01 | Lilly Sa | Procedimiento de preparacion de n-metil-3-fenil - (p-trifluorometilfenoxi) propilamina. |
| IT1283141B1 (it) * | 1996-07-11 | 1998-04-07 | Laporte Organics Francis S P A | Procedimento per la preparazione di n-metil-3-(p-trifluorometilfenossi)-3-fenilpropilamina e dei suoi |
| US6512010B1 (en) * | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
| US5830500A (en) * | 1996-07-22 | 1998-11-03 | Pentech Pharmaceuticals, Inc. | Low dose fluoxetine tablet |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| US6203817B1 (en) | 1997-02-19 | 2001-03-20 | Alza Corporation | Reduction of skin reactions caused by transdermal drug delivery |
| US5910319A (en) * | 1997-05-29 | 1999-06-08 | Eli Lilly And Company | Fluoxetine enteric pellets and methods for their preparation and use |
| CZ296282B6 (cs) * | 1997-11-14 | 2006-02-15 | Akzo Nobel N. V. | Farmaceutický prostredek |
| US5936124A (en) * | 1998-06-22 | 1999-08-10 | Sepacor Inc. | Fluoxetine process from benzoylpropionic acid |
| US6025517A (en) * | 1998-08-03 | 2000-02-15 | Sepracor Inc. | Fluoxetine process from benzoylacetonitrile |
| AU2180400A (en) * | 1999-01-13 | 2000-08-01 | Eli Lilly And Company | A pharmaceutical combination for the treatment of depression |
| FR2791345B1 (fr) * | 1999-03-26 | 2001-05-04 | Adir | Nouveaux derives du benzo[3,4]cyclobuta[1,2-c]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU3219800A (en) * | 1999-03-29 | 2000-10-16 | Eli Lilly And Company | Stereospecific method for preparing tomoxetine and intermediates thereof |
| CZ299712B6 (cs) * | 1999-09-03 | 2008-10-29 | Apbi Holdings, Llc | Použití dapoxetinu pro zvládnutí sexuální dysfunkce podáváním zpusobem podle potreby |
| US6677485B2 (en) | 1999-12-17 | 2004-01-13 | Ranbaxy Laboratories Limited | Process for the preparation of fluoxetine hydrochloride |
| GB0004153D0 (en) * | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel use |
| GB0004149D0 (en) * | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel compounds |
| GB0004152D0 (en) * | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel compounds |
| GB0004151D0 (en) * | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel use |
| US6273260B1 (en) | 2000-03-08 | 2001-08-14 | Eli Lilly And Company | Pharmaceutical packaging system |
| GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
| AU5702201A (en) * | 2000-04-13 | 2001-10-30 | Mayo Foundation | Abeta<sub>42</sub> lowering agents |
| RU2174391C1 (ru) * | 2000-10-24 | 2001-10-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Фармацевтическая композиция с антидепрессантной активностью |
| US20050013853A1 (en) * | 2000-11-29 | 2005-01-20 | Irit Gil-Ad | Anti-proliferative drugs |
| IL139975A0 (en) * | 2000-11-29 | 2002-02-10 | Univ Ramot | Anti proliferative drugs |
| US6310251B1 (en) | 2001-01-31 | 2001-10-30 | Grayson Walker Stowell | Form a of fluoxetine hydrochloride |
| US6313350B1 (en) | 2001-01-31 | 2001-11-06 | Grayson Walker Stowell | Form a of fluoxetine hydrochloride |
| US6316672B1 (en) | 2001-01-31 | 2001-11-13 | Grayson Walker Stowell | Form a of fluoxetine hydrochloride |
| US6310250B1 (en) | 2001-01-31 | 2001-10-30 | Grayson Walker Stowell | Form A of fluoxetine hydrochloride |
| US6258853B1 (en) | 2001-01-31 | 2001-07-10 | Grayson Walker Stowell | Form a of fluoxetine hydrochloride |
| HRP20030710A2 (en) * | 2001-03-06 | 2004-08-31 | Lilly Co Eli | Inhibitor of monoamine uptake |
| US6645946B1 (en) | 2001-03-27 | 2003-11-11 | Pro-Pharmaceuticals, Inc. | Delivery of a therapeutic agent in a formulation for reduced toxicity |
| AR035700A1 (es) * | 2001-05-08 | 2004-06-23 | Astrazeneca Ab | Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados |
| US7034059B2 (en) * | 2001-07-02 | 2006-04-25 | Sepracor Inc. | Methods of using norfluoxetine |
| US20030129186A1 (en) | 2001-07-25 | 2003-07-10 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| SE0102641D0 (sv) * | 2001-07-31 | 2001-07-31 | Astrazeneca Ab | Novel compounds |
| CA2452347A1 (en) * | 2001-07-31 | 2003-02-13 | Pharmacia & Upjohn Company | Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines |
| SE0102640D0 (sv) * | 2001-07-31 | 2001-07-31 | Astrazeneca Ab | Novel compounds |
| US20040170688A1 (en) * | 2001-08-06 | 2004-09-02 | Deshmukh Abhijit Mukund | Enteric formulation of fluoxetin |
| WO2003013480A1 (en) | 2001-08-06 | 2003-02-20 | Dr. Reddy's Laboratories Ltd. | Improved enteric formulation of fluoxetin |
| US6630454B2 (en) | 2001-09-10 | 2003-10-07 | Ramot At Tel-Aviv University Ltd. | Method and pharmaceutical composition for the treatment of cancer |
| EP1434763B1 (en) * | 2001-10-12 | 2018-01-17 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl vasopressin v1a antagonists |
| US20040034106A1 (en) * | 2001-11-06 | 2004-02-19 | Read Holly Ann | Treatment of anxiety disorders |
| ES2287338T3 (es) * | 2001-11-30 | 2007-12-16 | Eli Lilly And Company | Uso de inhibidores de recaptacion de norepinefrina para el tratamiento de trastornos de tics. |
| JP2005517647A (ja) * | 2001-12-11 | 2005-06-16 | イーライ・リリー・アンド・カンパニー | ノルエピネフリン再取り込み阻害物質の認知不全処置への使用 |
| EP2316468A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| US7326733B2 (en) * | 2002-05-31 | 2008-02-05 | The Forsyth Institute | Methods for increasing bone density |
| JP2004077714A (ja) * | 2002-08-15 | 2004-03-11 | Fuji Xerox Co Ltd | 光走査装置 |
| SE0203304D0 (sv) * | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Coumpounds |
| US6846957B2 (en) * | 2002-11-22 | 2005-01-25 | Board Of Regents, The University Of Texas System | Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor |
| US20040235925A1 (en) * | 2002-12-17 | 2004-11-25 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| WO2004091596A2 (en) * | 2003-04-18 | 2004-10-28 | Pharmacia & Upjohn Company Llc | Combination therapies for chronic obstructive pulmonary disease (copd) |
| JP4901474B2 (ja) * | 2003-05-30 | 2012-03-21 | ランバクシー ラボラトリーズ リミテッド | 置換ピロール誘導体 |
| US20050042284A1 (en) * | 2003-07-11 | 2005-02-24 | Myriad Genetics, Incorporated | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease |
| US20060100290A1 (en) * | 2003-07-28 | 2006-05-11 | Dunaway Leslie J | Treatment of allergic rhinitis and asthma |
| CA2537402C (en) | 2003-09-12 | 2009-05-05 | Pfizer Inc. | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors |
| US7402680B2 (en) * | 2003-09-17 | 2008-07-22 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds |
| DK1689721T3 (da) * | 2003-11-26 | 2010-09-20 | Pfizer Prod Inc | Aminopyrazolderivater som GSK-3-ihibitorer |
| JP5646126B2 (ja) | 2003-12-11 | 2014-12-24 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法 |
| WO2005065673A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Atomoxetine formulations |
| EP1732610A2 (en) * | 2004-03-26 | 2006-12-20 | Baylor University | Targeted serotonin reuptake inhibitors |
| WO2006001877A2 (en) * | 2004-04-13 | 2006-01-05 | Myriad Genetics, Inc. | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen |
| CA2567249A1 (en) * | 2004-04-19 | 2006-10-05 | Jds Pharmaceuticals, Llc | Lithium combinations, and uses related thereto |
| EP1745180A1 (en) * | 2004-04-29 | 2007-01-24 | Keystone Retaining Wall Systems, Inc. | Veneers for walls, retaining walls and the like |
| WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| CA2618985A1 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| WO2006037055A1 (en) * | 2004-09-27 | 2006-04-06 | Dr. Reddy's Laboratories Ltd. | Synthesis of atomoxetine hydrochloride |
| EP1730132A2 (en) * | 2004-12-23 | 2006-12-13 | Teva Pharmaceutical Industries Ltd | Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof |
| MX2007010931A (es) * | 2005-03-08 | 2007-10-16 | Teva Pharma | Formas cristalinas de (s)-(+)-n,n-dimetil-3-(1-naftaleniloxi)-3-(2 -tienil)propanamina oxalato y la preparacion ellas. |
| US20060270861A1 (en) * | 2005-03-14 | 2006-11-30 | Santiago Ini | Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine |
| JP2008534504A (ja) | 2005-03-22 | 2008-08-28 | アゼヴァン ファーマスーティカルズ，インコーポレイテッド | 月経前障害を治療するためのβラクタミルアルカン酸 |
| BRPI0610785A2 (pt) * | 2005-04-22 | 2016-09-13 | Wyeth Corp | polimorfo cristalino, processo para preparar o mesmo, forma cristalina, composição, e, métodos para tratar uma doença, distúrbios, e uma condição |
| GT200600164A (es) | 2005-04-22 | 2007-03-14 | Derivados de dihidrobenzofuranos y usos de los mismos | |
| AU2006239922A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists |
| PE20070093A1 (es) * | 2005-04-22 | 2007-02-07 | Wyeth Corp | Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c |
| CN101287411B (zh) | 2005-04-28 | 2013-03-06 | 普罗秋斯生物医学公司 | 药物信息系统及其用途 |
| US7485754B2 (en) * | 2005-07-08 | 2009-02-03 | Apotex Pharmachem Inc. | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers |
| US20070015138A1 (en) * | 2005-07-08 | 2007-01-18 | Braincells, Inc. | Methods for identifying agents and conditions that modulate neurogenesis |
| US20070015832A1 (en) * | 2005-07-14 | 2007-01-18 | Myriad Genetics, Incorporated | Methods of treating overactive bladder and urinary incontinence |
| CN101268068B (zh) * | 2005-07-19 | 2015-12-02 | 阿泽范药品公司 | β-内酰胺基苯丙氨酸、半胱氨酸和丝氨酸血管加压素拮抗剂 |
| US20070042034A1 (en) * | 2005-07-22 | 2007-02-22 | Myriad Genetics, Incorporated | High drug load formulations and dosage forms |
| US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| US7842717B2 (en) * | 2005-09-22 | 2010-11-30 | Teva Pharmaceutical Industries Ltd. | DNT-maleate and methods of preparation thereof |
| US20080207923A1 (en) * | 2005-09-22 | 2008-08-28 | Santiago Ini | Pure DNT-maleate and methods of preparation thereof |
| CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| KR101329112B1 (ko) * | 2005-11-08 | 2013-11-14 | 랜박시 래보러터리스 리미티드 | (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법 |
| CN1304360C (zh) * | 2005-12-12 | 2007-03-14 | 天津大学 | N,n－二甲基－3－羟基－3－芳基丙胺的制备方法 |
| MX2007011611A (es) * | 2006-01-23 | 2007-10-18 | Teva Pharma | Fumarato de dnt y metodos de preparacion de ellos. |
| FR2912057B1 (fr) * | 2007-02-07 | 2009-04-17 | Sanofi Aventis Sa | Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| CA2643199A1 (en) * | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AR059838A1 (es) * | 2006-03-14 | 2008-04-30 | Ranbaxy Lab Ltd | Formulaciones para dosis estabilizantes de estatina |
| MX2008012094A (es) * | 2006-03-24 | 2008-10-03 | Wyeth Corp | Nuevas combinaciones terapeuticas para el tratamiento de la depresion. |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | アンジオテンシン調節による神経新生 |
| CN101448815A (zh) * | 2006-05-23 | 2009-06-03 | 特瓦制药工业有限公司 | 度洛西汀hci多晶型物 |
| US20080033045A1 (en) * | 2006-07-07 | 2008-02-07 | Myriad Genetics, Incorporated | Treatment of psychiatric disorders |
| US20080153896A1 (en) * | 2006-07-14 | 2008-06-26 | Gyan Chand Yadav | Polymorphic Forms of an HMG-CoA Reductase Inhibitor and Uses Thereof |
| TW200817003A (en) * | 2006-07-31 | 2008-04-16 | Sanofi Aventis | Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor |
| WO2008026227A2 (en) * | 2006-08-28 | 2008-03-06 | Matrix Laboratories Ltd | A process for the preparation of atomoxetine hydrochloride |
| AU2007292848A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100016274A1 (en) * | 2006-09-14 | 2010-01-21 | Koppel Gary A | Beta-lactam cannabinoid receptor modulators |
| WO2008036682A2 (en) | 2006-09-18 | 2008-03-27 | Raptor Pharmaceutical Inc. | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates |
| AU2007299920A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| ITMI20061987A1 (it) | 2006-10-16 | 2008-04-17 | Archimica Srl | Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine. |
| WO2008062473A1 (en) * | 2006-10-31 | 2008-05-29 | Cadila Healthcare Limited | Process for preparing atomoxetine hydrochloride |
| FR2910319B1 (fr) | 2006-12-20 | 2011-06-03 | Substipharm Dev | Formulations pharmaceutiques dispersibles contenant de la fluoxetine |
| US20080167363A1 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc | Modulation of Neurogenesis By Melatoninergic Agents |
| AU2008204800A1 (en) * | 2007-01-11 | 2008-07-17 | Braincells, Inc. | Modulation of neurogenesis with use of modafinil |
| WO2008122019A1 (en) * | 2007-04-02 | 2008-10-09 | Cypress Biosciences, Inc. | Improving the tolerability of both mirtazapine and reboxetine by using them in combination |
| US20090137598A1 (en) | 2007-06-21 | 2009-05-28 | Veroscience, Llc | Method of treating metabolic disorders and depression with dopamine receptor agonists |
| WO2009141833A2 (en) * | 2008-04-17 | 2009-11-26 | Ind-Swift Laboratories Limited | An improved process for synthesizing highly pure atomoxetine |
| US20110034565A1 (en) | 2008-04-18 | 2011-02-10 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| DK3395372T3 (da) | 2009-02-20 | 2022-04-19 | Enhanx Biopharm Inc | System til afgivelse af glutathion-baseret medikament |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EP2427178B1 (en) | 2009-05-06 | 2023-01-04 | Laboratory Skin Care, Inc. | Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same |
| WO2011027359A2 (en) | 2009-07-30 | 2011-03-10 | Matrix Laboratories Ltd | Novel process for the preparation of 4-hydroxy atomoxetine |
| EP2348120B1 (en) | 2009-12-30 | 2014-06-11 | Universität Wien | Enzymatic reduction of 1-phenylpropanone and derivatives thereof |
| ES2662350T3 (es) | 2010-07-01 | 2018-04-06 | Azevan Pharmaceuticals, Inc. | Procedimientos para el tratamiento del trastorno por estrés postraumático |
| WO2012020418A1 (en) | 2010-08-12 | 2012-02-16 | Matrix Laboratories Ltd | Novel polymorphs of 4-hydroxy atomoxetine hydrochloride |
| US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
| WO2012123922A1 (en) | 2011-03-17 | 2012-09-20 | Lupin Limited | Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor |
| EA201590047A1 (ru) | 2012-07-31 | 2015-09-30 | Сановел Хайван Саглиги Юрюнлери Санайи Ве Тиджарет А.С. | Применение флуоксетина для увеличения мясной и молочной продуктивности |
| US20150190352A1 (en) | 2012-07-31 | 2015-07-09 | Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret Anonim Sirketi | Use of fluoxetine in animals |
| WO2014046544A1 (en) | 2012-09-21 | 2014-03-27 | Aapa B.V. | Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators |
| KR20160130853A (ko) | 2014-03-28 | 2016-11-14 | 아제반 파마슈티칼스, 인코퍼레이티드 | 신경변성 질환을 치료하기 조성물 및 방법 |
| CN105777706B (zh) * | 2014-12-25 | 2019-08-23 | 江苏恩华药业股份有限公司 | 一种3-[(苯并[d][1, 3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用 |
| AU2018333051B2 (en) | 2017-09-15 | 2024-03-21 | Azevan Pharmaceuticals, Inc. | Compositions and methods for treating brain injury |
| JP7739256B2 (ja) | 2019-07-19 | 2025-09-16 | バイオエクセル セラピューティクス，インコーポレイテッド | 鎮静作用のないデクスメデトミジン治療レジメン |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2683742A (en) * | 1951-02-23 | 1954-07-13 | Searle & Co | Nu, nu-disubstituted omega-arylmethoxy-omega-arylalkylamine derivatives |
| ES251290A1 (es) * | 1958-08-21 | 1960-04-01 | Parke Davis & Co | Un procedimiento para la producciën de alcohilaminas arilsustituidas |
| US3132179A (en) * | 1959-08-27 | 1964-05-05 | Sterling Drug Inc | Ethers of alpha-hydroxymethyl-beta-monocarbocyclic aryl ethyl amines and their preparation |
| US3253040A (en) * | 1962-12-10 | 1966-05-24 | Union Carbide Corp | Process for the production of primary 3-hydrocarbyloxypropylamines |
-
1974
- 1974-01-10 US US05/432,379 patent/US4314081A/en not_active Expired - Lifetime
- 1974-12-30 DK DK688974AA patent/DK140430B/da not_active IP Right Cessation
- 1974-12-30 RO RO7490077A patent/RO70660A/ro unknown
- 1974-12-30 RO RO7480996A patent/RO69763A/ro unknown
-
1975
- 1975-01-01 AR AR257198A patent/AR205633A1/es active
- 1975-01-01 AR AR259904A patent/AR205577A1/es active
- 1975-01-01 AR AR259905A patent/AR205578A1/es active
- 1975-01-02 ZA ZA00750032A patent/ZA7532B/xx unknown
- 1975-01-02 IE IE1/75A patent/IE40346B1/xx not_active IP Right Cessation
- 1975-01-02 CA CA217,287A patent/CA1051034A/en not_active Expired
- 1975-01-03 DE DE19752500110 patent/DE2500110A1/de active Granted
- 1975-01-03 PH PH16672A patent/PH11652A/en unknown
- 1975-01-07 NL NLAANVRAGE7500186,A patent/NL181654C/xx active Protection Beyond IP Right Term
- 1975-01-07 CH CH10275A patent/CH609675A5/xx not_active IP Right Cessation
- 1975-01-08 AT AT10275A patent/AT336000B/de active Protection Beyond IP Right Term
- 1975-01-08 CS CS75150A patent/CS189680B2/cs unknown
- 1975-01-09 BG BG028686A patent/BG26192A3/xx unknown
- 1975-01-09 SU SU752101119A patent/SU1005655A3/ru active
- 1975-01-09 GB GB898/75A patent/GB1493961A/en not_active Expired
- 1975-01-09 FR FR7500543A patent/FR2257288B1/fr not_active Expired
- 1975-01-09 BG BG030202A patent/BG23212A3/xx unknown
- 1975-01-09 YU YU0032/75A patent/YU36915B/xx unknown
- 1975-01-09 BE BE1006387A patent/BE824255A/xx not_active IP Right Cessation
- 1975-01-09 SE SE7500215A patent/SE412906B/xx active Protection Beyond IP Right Term
- 1975-01-10 DD DD183594A patent/DD118613A5/xx unknown
- 1975-01-10 JP JP50005888A patent/JPS5939418B2/ja not_active Expired
- 1975-01-10 ES ES433720A patent/ES433720A1/es not_active Expired
-
1981
- 1981-04-13 YU YU1215/81A patent/YU37308B/xx unknown
- 1981-05-13 YU YU1214/81A patent/YU37307B/xx unknown
-
1993
- 1993-06-29 NL NL930108C patent/NL930108I2/nl unknown
-
1994
- 1994-02-25 BG BG098576A patent/BG60761B2/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2500110C2 (OSRAM) | ||
| DE2907217C2 (de) | 3-Phenyl-3-phenoxypropylamin-Derivate und deren Salze, deren Herstellung und diese enthaltende Arzneimittel | |
| DD144763A5 (de) | Verfahren zur herstellung von phenethanolaminen | |
| DE2317710A1 (de) | Dopaminderivate | |
| AT368130B (de) | Verfahren zur herstellung von neuen 9-aminoalkyl- fluorenen und von deren salzen | |
| DE2720545B2 (de) | Derivate des 2,4-Diamino-6,7-dimethoxychinazolins, ihre Herstellung und pharmazeutische Mittel | |
| DE2524053A1 (de) | 1-aethyl-3a-substituiertes-phenyl- decahydroisochinoline | |
| DE2817370A1 (de) | Phenyltetrazolyloxy-propanolamine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel | |
| DD139842A5 (de) | Verfahren zur herstellung quaternaerer ammoniumsalze von phenylpropylaminen und phenylbutylaminen | |
| DE2331438A1 (de) | Neue derivate der cumarine | |
| CH623562A5 (OSRAM) | ||
| DE2166662C3 (de) | Dibenzothiazepinderivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel | |
| DE2522218B2 (de) | Zusammensetzung für die Human- oder Veterinärmedizin, Methylaminderivate und Verfahren zu deren Herstellung | |
| DE2507429A1 (de) | Aminosaeureester, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| AT337161B (de) | Verfahren zur herstellung von neuen 3-phenoxy-3-phenylpropylaminen und deren saureadditionssalzen | |
| DE2833892A1 (de) | 12h-dibenzo eckige klammer auf d,g eckige klammer zu eckige klammer auf 1,3,6 eckige klammer zu dioxazocinderivate, solche enthaltende arzneimittel und verfahren zur herstellung derselben | |
| DE2311067C2 (de) | Diphenylmethoxyäthylamine, Verfahren zu deren Herstellung und Verwendung von Diphenylmethoxyäthylaminen bei der Bekämpfung der Parkinson-Krankheit | |
| DE2725245A1 (de) | Methylaminderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische oder veterinaermedizinische zusammensetzungen | |
| DE2738131A1 (de) | Aminoketone, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| DE2227842C3 (de) | Diphenylcyclopentane und diese enthaltende Arzneimittel | |
| DE2539941C2 (de) | Basische Benzyloxyalkyl-Derivate, deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE1770104C3 (de) | 2- [(3,4-Dichlorphenoxy)-methyl] -2-unidazolin und seine Salze | |
| AT278785B (de) | Verfahren zur Herstellung von neuen Piperidinderivaten und ihren Salzen | |
| DE2025341C3 (de) | 2,4,6-Trimethoxybenzoesäure-2-morpholinoäthyl-ester und seine Säureadditionssalze, Verfahren zu deren Herstellung und deren Verwendung als Wirkstoff in pharmazeutischen Zubereitungen | |
| AT267511B (de) | Verfahren zur Herstellung neuer 1-Phenyl-1-(2'-aminoäthyl)-indene und ihrer Salze |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8128 | New person/name/address of the agent |
Representative=s name: SPOTT, G., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW., 800 |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |